LYON, France--(BUSINESS WIRE)--ResMed, a pioneer and global leader in sleep and respiratory medicine, has announced the launch of its ResMed Air Solutions range, led by the intelligent, cloud-enabled AirCurve 10 CS PaceWave™ with AirView system. This is the first device to combine remote monitoring with ResMed’s innovative PaceWave™ Minute Ventilation (MV)-Adaptive-Servo-Ventilation (ASV) therapy. Through a unique patented algorithm, PaceWaveTM MV-ASV allows a patient’s breathing during sleep to be intelligently stabilised and monitored, offering an option to treat a wide variety of patients with central sleep apnoea (CSA), a specific form of sleep-disordered breathing. This is especially relevant for those suffering from Cheyne-Stokes Respiration (CSR), a pattern of CSA commonly seen in patients with heart failure.1,2,3 CSA/CSR is thought to affect up to 50%4,5,6 of patients with chronic heart failure and has been linked to increased mortality and morbidity in this patient population.7 The use of PaceWaveTM MV-ASV therapy to treat CSA in patients with chronic heart failure is currently being investigated in SERVE-HF, the world’s largest randomised trial in this field.
Help employers find you! Check out all the jobs and post your resume.
